An elevated cardiac troponin level often changes the trajectory of a clinical encounter. A patient presents with pneumonia, severe anemia, tachycardia, hypoxemia, or another acute illness, and the troponin comes back above the laboratory’s upper reference limit. The immediate question is often: “Is this a myocardial infarction?” The answer is not necessarily.
The Fifth Universal Definition of Myocardial Infarction (UDMI), released in 2026 by the European Society of Cardiology, American College of Cardiology, American Heart Association, and World Heart Federation, places renewed emphasis on an important distinction: Myocardial injury is not synonymous with myocardial infarction. The updated definition also replaces the previous numerical classification of myocardial infarction with three clinical categories: primary, secondary, and procedure-related myocardial infarction.
Start with the troponin, but do not stop there
The Fifth UDMI defines myocardial injury when cardiac troponin is above the assay-specific 99th percentile upper reference limit. Acute myocardial injury is characterized by a rise and/or fall in troponin, whereas persistent elevation without a significant change may represent chronic myocardial injury.
Real physician voices, twice a week
Free, and one click to unsubscribe.
This distinction matters because many acute and chronic conditions can produce myocardial injury without an infarction. A patient with sepsis may have an elevated troponin. So may a patient with pulmonary embolism, heart failure, renal dysfunction, myocarditis, severe hypertension, or sustained tachyarrhythmia. The biomarker tells us that myocardial injury has occurred; it does not, by itself, tell us why.
The next question should be: Is there evidence of acute myocardial ischemia? Under the Fifth UDMI, myocardial infarction requires acute myocardial injury together with evidence of myocardial ischemia. Depending on the clinical situation, this may include ischemic symptoms or signs, new ischemic ECG changes, pathological Q waves, or imaging evidence of a new loss of viable myocardium or a new regional wall-motion abnormality consistent with an ischemic cause. That distinction provides a useful framework at the bedside.
A high troponin in a sick patient is not automatically a secondary MI
Consider a patient with severe pneumonia, oxygen saturation of 84 percent, sinus tachycardia, and a markedly elevated troponin. It may be tempting to label this as secondary myocardial infarction simply because the patient clearly has an oxygen supply-demand imbalance. But the presence of a plausible trigger is not enough.
Under the Fifth UDMI, secondary myocardial infarction occurs when an alternative acute condition produces myocardial oxygen supply-demand imbalance and there is evidence supporting myocardial ischemia. The new definition specifically aims to improve specificity in situations that can otherwise be difficult to distinguish from acute myocardial injury.
If the same patient has no ischemic symptoms, no new ischemic ECG changes, and no imaging evidence suggesting an ischemic event, an elevated and dynamic troponin may represent acute myocardial injury rather than myocardial infarction. This is more than a semantic distinction. The diagnosis of MI can influence subsequent investigation, secondary prevention, documentation, and communication among clinicians.
When should we think about secondary myocardial infarction?
The clinical context remains important. Tachyarrhythmia, hypoxemia, anemia, hypotension, and severe hypertension can create an imbalance between myocardial oxygen supply and demand. In a secondary MI, however, the clinician should establish that the imbalance has resulted in myocardial ischemia rather than assuming that it has from the troponin result alone.
For example, imagine two patients with hemoglobin of 6.5 g/dL and elevated troponin. The first has no chest discomfort, no ischemic ECG changes, and no new regional wall-motion abnormality. The overall picture may be acute myocardial injury associated with severe anemia.
The second develops typical ischemic chest discomfort, new ischemic ECG changes, and a new regional wall-motion abnormality while severely anemic. In that setting, the evidence for myocardial infarction becomes considerably stronger.
The trigger may be similar. The diagnosis is not.
Do not ignore underlying coronary artery disease
Another practical challenge is deciding how much weight to give known or newly identified coronary artery disease. The presence of coronary artery disease does not automatically turn myocardial injury into myocardial infarction. At the same time, dismissing an elevated troponin as simply “demand” because the patient is acutely ill may overlook clinically important coronary disease.
Prospective studies of patients diagnosed with type 2 MI under the previous definition found a substantial burden of coronary artery disease and cardiac abnormalities. These findings support considering appropriate cardiac or coronary assessment when the diagnosis or underlying mechanism remains uncertain.
The Fifth UDMI therefore places greater emphasis on cardiac and coronary imaging when appropriate. Depending on the clinical presentation, this may include echocardiography, coronary CT angiography, invasive coronary angiography, cardiac MRI, or other appropriate testing.
The goal is not to send every patient with elevated troponin for invasive angiography. It is to use the available evidence to determine whether an ischemic mechanism is actually present.
The ECG still matters
In an era dominated by high-sensitivity troponin, it is easy to allow the laboratory result to dominate the diagnostic process. That is a mistake.
The ECG remains one of the fastest ways to look for evidence of myocardial ischemia. New ischemic ST-segment or T-wave changes and pathological Q waves can contribute directly to the diagnosis of myocardial infarction under the Fifth UDMI. The ECG should therefore be interpreted alongside the patient’s symptoms, serial troponin results, hemodynamic status, and imaging, not after the troponin has already determined the diagnosis.
Sex-specific troponin thresholds add another layer
The Fifth UDMI also reinforces the use of sex-specific 99th percentile upper reference limits for cardiac troponin. This is important because cardiac troponin concentrations differ between men and women, and the use of a single threshold may contribute to under-recognition of myocardial injury and myocardial infarction in women.
However, sex-specific thresholds should not be interpreted as a stand-alone diagnostic tool. Their clinical impact can vary according to the assay and population being tested. The practical message is straightforward: Clinicians should know which assay is being used, understand its validated reference limits, and interpret the result within the entire clinical picture.
A useful bedside sequence
When confronted with an elevated troponin, a simple sequence can help.
- First: Is there myocardial injury? Determine whether the troponin exceeds the assay-specific 99th percentile and whether there is a rise and/or fall suggesting acute injury.
- Second: Is there evidence of ischemia? Look for ischemic symptoms, ECG changes, imaging findings, or other objective evidence.
- Third: If there is ischemia, what is the mechanism? Consider primary coronary pathology, secondary oxygen supply-demand imbalance, or a procedure-related cause.
- Fourth: If the patient has a secondary trigger, do not stop the evaluation there. Ask whether underlying coronary disease or another cardiac condition could be contributing.
This approach may prevent two opposite errors: calling every elevated troponin a myocardial infarction, or dismissing every elevated troponin in an acutely ill patient as “demand ischemia.”
The distinction matters
Distinguishing myocardial injury from secondary MI should not lead clinicians to underestimate either condition. Patients with secondary MI and acute myocardial injury can have substantial cardiovascular risk, and prospective studies have demonstrated a significant burden of coronary and cardiac disease among patients previously classified as having type 2 MI.
The clinical task, therefore, is not simply to decide whether the troponin “counts.” It is to understand what the troponin is telling us. The Fifth Universal Definition provides a clearer framework: Myocardial injury is a biomarker-defined condition; myocardial infarction requires myocardial injury in the setting of myocardial ischemia.
For clinicians facing an elevated troponin in the emergency department, hospital ward, or primary-care setting, keeping that distinction at the center of the assessment may be one of the most useful lessons from the new definition.
Tarik Alsalih is a physician in Egypt.
